Roche Signs a Clinical Program Agreement with Vaccibody to Evaluate VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer
Shots:
- Roche & Vaccibody collaborated to assess the combination of VB10.16 + Tecentriq in P-II- for 50 patients with advanced cervical cancer to evaluate its safety- tolerability- immunogenicity and efficacy
- The combination trial agreement is built upon the trial assessing VB10.16 monothx in patients with precancerous cervical lesion. Vaccibody plans for the onset of P-II for the combination in H2’19
- Tecentriq (atezolizumab) is a mAb inhibiting PD-L1 while blocking its interaction with PD-1 and B7.1 receptor. VB10.16 is a DNA vaccine- targeting HPV16 induced malignancies and is evaluated in P-I/IIa study for patients with pre-cancerous HPV16 induced high grade cervical intraepithelial neoplasia
Ref: Vaccibody | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com